Table 2.
Secondary efficacy endpoints in the Japanese subgroup versus overall population (ITT population)
| Endpoints (months) | Japanese subgroup | Overall population | ||||
|---|---|---|---|---|---|---|
| AAP (N = 35) | Placebo (N = 35) | Hazard ratio (95% CI) | AAP (N = 597) | Placebo (N = 602) | Hazard ratio (95% CI); P value | |
| Median time to pain progression | NR | 10.15 | 0.68 (0.35,1.33) | NR | 16.6 | 0.70 (0.58;0.83); P < 0.0001 |
| Median time to PSA progression | NR | 9.26 | 0.19 (0.09,0.38) | 33.2 | 7.4 | 0.30 (0.26;0.35); P < 0.0001 |
| Median time to next skeletal-related event | NR | NR | 2.41 (0.82,7.06) | NR | NR | 0.70 (0.54;0.92); P = 0.0086 |
| Median time to chemotherapy | NR | 35.55 | 0.43 (0.18,1.02) | NR | 38.9 | 0.44 (0.35;0.56); P < 0.0001 |
| Median time to subsequent prostate cancer therapy | NR | 18.56 | 0.28 (0.14,0.56) | NR | 21.6 | 0.42 (0.35;0.50); P < 0.0001 |
AAP, abiraterone acetate plus prednisone; NR, not reached; PSA, prostate-specific antigen.